Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Biogen (BIIB – Research Report). The associated price target ...

Some experts have said the discovery of donanemab, by Eli Lilly, could be a “turning point” after a successful clinical trial ...

The Western New York Chapter of the Alzheimer’s Association will offer a free education program on recognizing and understanding Alzheimer’s disease and dementia at 10 a.m. Thursday at ...

The facility at a business park in Raheen, Limerick, was first announced in 2022 and this is the second time that Lilly has ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

G&L taps new hire to lead growth. G&L Healthcare Advisors, a Madison, New Jersey consultancy specialising in regulatory and ...

Alzheimer disease research is yielding breakthroughs with blood tests and brain scans that can enhance early diagnosis, while ...

A similar treatment involving another drug, donanemab, is underway. Frederiksen doubts that this will gain EMA approval either. “I believe EMA will reach the same decision because the current results ...

Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and the evolving role of pharmacy benefit managers in the market.

Dementia is the leading cause of death in the UK but, according to new research, almost half of cases can prevented and ...